* PMV Pharmaceuticals Inc PMVP.OQ reported a quarterly
adjusted
loss of 38 cents per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 41 cents per share.
* Reported revenue was zero; analysts expected zero.
* PMV Pharmaceuticals Inc's reported EPS for the quarter was
a
loss of 38 cents.
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* PMV Pharmaceuticals Inc shares had risen by 20.6% this
quarter and lost 25.6% so far this year.
* The company reported a quarterly loss of $17.31 million.
* Wall Street's median 12-month price target for PMV
Pharmaceuticals Inc is $41.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data August 11
at 01:00 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2022 -0.41 -0.38 Beat
Mar. 31 2022 -0.40 -0.41 Missed
Dec. 31 2021 -0.35 -0.40 Missed
Sep. 30 2021 -0.30 -0.33 Missed